DE2950909A1 - PEPTIDES CONTAINING AMINOCITRONIC ACID IN PEPTIDE BINDING - Google Patents

PEPTIDES CONTAINING AMINOCITRONIC ACID IN PEPTIDE BINDING

Info

Publication number
DE2950909A1
DE2950909A1 DE19792950909 DE2950909A DE2950909A1 DE 2950909 A1 DE2950909 A1 DE 2950909A1 DE 19792950909 DE19792950909 DE 19792950909 DE 2950909 A DE2950909 A DE 2950909A DE 2950909 A1 DE2950909 A1 DE 2950909A1
Authority
DE
Germany
Prior art keywords
acid
peptides
aminocitric
aminocitronic
peptide binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE19792950909
Other languages
German (de)
Inventor
Günther Prof. Dr.med. 6072 Dreieich Wilhelm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to DE19792950909 priority Critical patent/DE2950909A1/en
Priority to EP19810900144 priority patent/EP0041991A1/en
Priority to PCT/EP1980/000148 priority patent/WO1981001709A1/en
Priority to JP50032881A priority patent/JPS57500104A/ja
Publication of DE2950909A1 publication Critical patent/DE2950909A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof

Abstract

The oligopeptides or polypeptides are comprised of a plurality of amino acids which are interconnected by peptidic bonds, at least one of these amino acids being a stereoisomer of an amino acid of the formula C<u6>uH<u9>uO<u7>uN with a molecular weight of 207 (aminocitric acid; ACS). The peptides are obtained from different organic tissues and bacterial cells.

Description

Peptide, die Aminocitronensäure in Peptidbindung enthaltenPeptides that contain aminocitric acid in a peptide bond

Es ist bekannt, daß Peptide aus Aminosäuren bestehen, die über Peptidbindungen verbunden sind. Differente Peptide werden in großer Zahl und mit unterschiedlichen biologischen Wirkungen beschrieben.It is known that peptides consist of amino acids that have peptide bonds are connected. Different peptides are produced in large numbers and with different biological effects described.

Es wurde nun gefunden, daß Peptide in biologischen Organismen vorkommen, wobei die Peptide Aminocitronensäure (Molekulargewicht 207,15) enthalten. Derartige Peptide sind bisher nicht bekannt.It has now been found that peptides occur in biological organisms, the peptides containing aminocitric acid (molecular weight 207.15). Such Peptides are not yet known.

Bei der bekannten hohen Spezifität von Peptiden ist die Auffindung einer neuen Peptidgruppe in Organismen ein großer Fortschritt für Biologie und Medizin. So besitzt zum Beispiel eine Gruppe dieser Peptide spezifische Antigeneigenschaften.With the known high specificity of peptides, the discovery a new group of peptides in organisms represents a major advance in biology and medicine. For example, one group of these peptides has specific antigenic properties.

Der Nachweis von Aminocitronensäure in den erfindungsgemäßen Peptiden kann zum Beispiel dadurch geführt werden, daß man die Peptide einer Hydrolyse unterzieht und die freigesetzten Aminosäuren in einem Aminosäureanalysator auftrennt.The detection of aminocitric acid in the peptides according to the invention can for example be carried out by subjecting the peptides to hydrolysis and separating the released amino acids in an amino acid analyzer.

Der Aminocitronensäurepiek erscheint bei üblichen Bedingungen vor der Asparaginsäure. Die Überprüfung kann zum Beispiel mit synthetisch hergestellter reiner Aminocitronensäure (1) erfolgen.The aminocitric acid peak appears under normal conditions of aspartic acid. The verification can for example with synthetically produced pure aminocitric acid (1).

Im Massenspektrographen erscheint zum Beispiel bei Verwendung einer Lasers zur Ionisation der m-1Piek der eluierten Aminocitronensäure bei Molekulargewicht 206. Die synthetisch hergestellte reine Aminocitronensäure stellt sich bei diesem Verfahren ebenfalls als m-1 Piek mit dem Molekulargewicht 206 dar.For example, when using a, appears in the mass spectrograph Laser for ionizing the m-1Piek of the eluted aminocitric acid at molecular weight 206. The synthetically produced pure aminocitric acid arises with this The method is also represented as an m-1 piece with a molecular weight of 206.

Unterzieht man die eluierte Aminocitronensäure zum Beispiel einer PerJodsäureoxydation, so erhält man unter Abspaltung von Ammoniak Ketocarbonsäure.Subjecting the eluted aminocitric acid to, for example Periodic acid oxidation, ketocarboxylic acid is obtained with elimination of ammonia.

Die aminocitronensäurehaltigen Peptide kommen weit verbreitet in biologischen Organismen vor. Sie sind zum Beispiel bei eukaryontischen Zellen im Zellkern nachweisbar. Eine Gewinnungsmöglichkeit besteht zum Beispiel darin, daß man einen Nucleoproteinkomplex aus den Organismen abtrennt und die aminocitronensäurehaltigen Peptide daraus mit einer der üblichen Methoden der Eiweißchemie isoliert.The aminocitric acid containing peptides are widely used in biological organisms. They are, for example, in eukaryotic cells Cell nucleus detectable. One way of obtaining is, for example, that one separates a nucleoprotein complex from the organisms and the aminocitric acid Peptides isolated from it using one of the usual methods of protein chemistry.

Beispiel 1 Erfindungsgemäße Peptide, die Aminocitronensäure in Peptidbindung enthalten, können zum Beispiel auf folgende Weise erhalten werden Aus biologischen Organismen oder Geweben, zum Beispiel Kalbsthymus, wird nach der Vorschrift von G.Wilhelm ( 2 ) ein Nucleoprotein abgetrennt. Nach Lyophilisation wird das Nucleoprotein zum Beispiel in Wasser gelöst. Anschließend wird eine Filtration, zum Beispiel unter Verwendung einer UM2-Membran der Firma Amicon, durchgeführt. Im Filtrat sind aminocitronensäurehaltige Peptide nachweisbar. Die weitere Isolierung von einzelnen Peptiden kann mit den üblichen Verfahren der Eiweiß chemie durchgeführt werden. Example 1 Peptides According to the Invention Containing Aminocitric Acid in Peptide Linkage can be obtained, for example, in the following manner From biological Organisms or tissues, for example calf thymus, are made according to the prescription of G.Wilhelm (2) separated a nucleoprotein. After lyophilization, the nucleoprotein becomes for example dissolved in water. This is followed by a filtration, for example under Using a UM2 membrane from Amicon. There are aminocitric acid in the filtrate Detectable peptides. The further isolation of individual peptides can be carried out with the normal protein chemistry procedures are carried out.

Beispiel 2 Trennt man auf dem im Beispiel eins angeführten Weg aus Tuberkelbakterien aminocitronensäurehaltige Peptide ab, so verursachen sie bei intracutaner InJektion bei einem tuberkulinpositiven Menschen eine verzögerte immunologische Hautreaktion. Example 2 One separates out on the way given in example one Tubercle bacteria remove aminocitric acid-containing peptides, so they cause intracutaneous InJection in a tuberculin-positive human a delayed immunological Skin reaction.

Literatur 1. Guthrie, Robert William Kirstead, Richard Wightman Citronensäurederivate Deutsches Patentamt, Offenlegungsschrift 2258257, Anmeldetag 28.November 1972 2. Wilhelm,G.: Über ein aus menschlichen und tierischen Geweben isoliertes Nucleoprotein mit kollagenfällenden Eigenschaften.Literature 1. Guthrie, Robert William Kirstead, Richard Wightman Citric Acid Derivatives German Patent Office, Offenlegungsschrift 2258257, filing date November 28, 1972 2. Wilhelm, G .: About a nucleoprotein isolated from human and animal tissues with collagen-precipitating properties.

I. Abtrennung und Charakterisierung des Nucleoproteins. I. Separation and characterization of the nucleoprotein.

Z.Naturforschung 21b (1966) 797 - 798 Z. Naturforschung 21b (1966) 797-798

Claims (4)

Patentansprüche 3 Peptide dadurch gekennzeichnet,daß sie Aminocitronensäure in Peptidbindung enthalten. Patent claims 3 peptides characterized in that they contain aminocitric acid contained in peptide bond. 2. Peptide nach Anspruch 1 dadurch gekennzeichnet, daß eine Gruppe von ihnen spezifische Antigene darstellen. 2. Peptides according to claim 1, characterized in that a group of them represent specific antigens. 3. Verwendung von Peptiden nach Anspruch 1 als Arzneimittel, in einem üblichen pharmazeutischen Träger, gegebenenfalls in Verbindung mit üblichen pharmazeutischen Additiven. 3. Use of peptides according to claim 1 as medicaments in one customary pharmaceutical carriers, optionally in conjunction with customary pharmaceuticals Additives. 4. Verwendung von Peptiden nach Anspruch 1 zur spezifischen Beeinflussung von biologischen Systemen. 4. Use of peptides according to claim 1 for specific influencing of biological systems.
DE19792950909 1979-12-18 1979-12-18 PEPTIDES CONTAINING AMINOCITRONIC ACID IN PEPTIDE BINDING Withdrawn DE2950909A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
DE19792950909 DE2950909A1 (en) 1979-12-18 1979-12-18 PEPTIDES CONTAINING AMINOCITRONIC ACID IN PEPTIDE BINDING
EP19810900144 EP0041991A1 (en) 1979-12-18 1980-12-16 Polypeptides
PCT/EP1980/000148 WO1981001709A1 (en) 1979-12-18 1980-12-16 Polypeptides
JP50032881A JPS57500104A (en) 1979-12-18 1980-12-16

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19792950909 DE2950909A1 (en) 1979-12-18 1979-12-18 PEPTIDES CONTAINING AMINOCITRONIC ACID IN PEPTIDE BINDING

Publications (1)

Publication Number Publication Date
DE2950909A1 true DE2950909A1 (en) 1981-06-25

Family

ID=6088820

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19792950909 Withdrawn DE2950909A1 (en) 1979-12-18 1979-12-18 PEPTIDES CONTAINING AMINOCITRONIC ACID IN PEPTIDE BINDING

Country Status (4)

Country Link
EP (1) EP0041991A1 (en)
JP (1) JPS57500104A (en)
DE (1) DE2950909A1 (en)
WO (1) WO1981001709A1 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1617938A1 (en) * 1966-04-19 1971-04-15 Magnin Pierre Marcel Process for the manufacture of a new hormone product
DE1617950A1 (en) * 1967-08-14 1971-05-19 Univ Yeshiva Process for influencing the immunity or resistance of a host organism
US3937816A (en) * 1970-07-21 1976-02-10 Solco Basel Ag Growth regulating compositions extracted from spleen
DE2110436C3 (en) * 1971-03-04 1981-08-13 Laboratori farmaco-biologici Ellem S.p.A., Milano Process for the preparation of an antileucopenic and antibody-forming thymus extract from calf thymus
IL47645A (en) * 1975-07-04 1980-10-26 Yeda Res & Dev Substantially pure and uniform thymic hormone thf,its preparation and pharmaceutical compositions containing it
DE2815758C3 (en) * 1978-04-12 1982-02-18 R. & Z. Vermögensverwaltungsgesellschaft mbH, 4150 Krefeld Peptide complexes from organisms containing DNA

Also Published As

Publication number Publication date
EP0041991A1 (en) 1981-12-23
JPS57500104A (en) 1982-01-21
WO1981001709A1 (en) 1981-06-25

Similar Documents

Publication Publication Date Title
DE2450355C2 (en)
EP0149468A2 (en) Biologically active substance with hormonal characteristics, process for its preparation and use of histons for medicinal ends
DE2847608A1 (en) GLYCOPEPTIDES AND THE METHOD OF MANUFACTURING THEREOF
DE3448152C2 (en)
EP0346501A1 (en) Pharmaceutical preparation for treating immunodeficiency conditions
EP0046979A1 (en) Insulin analogues
DE2921216C2 (en)
ATE74761T1 (en) USE OF PLANT POLLEN EXTRACTS FOR THE MANUFACTURE OF TUMOR CELL GROWTH INHIBITING PHARMACEUTICAL PREPARATIONS AND PROCESS FOR THEIR MANUFACTURE.
DE2853002A1 (en) POLYPEPTIDES AND THE METHOD FOR MANUFACTURING THEM
DE2950909A1 (en) PEPTIDES CONTAINING AMINOCITRONIC ACID IN PEPTIDE BINDING
EP0080194B1 (en) Peptides and process for their preparation
DE1617332C3 (en) Method for isolating a water-soluble protein-metal chelate with anti-inflammatory activity
CH622527A5 (en)
DE1076888B (en) Process for the production of active substances that promote breathing for therapeutic purposes
DE2720041A1 (en) HEART STRENGTHENING AGENT
DE2939522C2 (en) Cyclo- (N??? -Kallidin), N??? -Arginyl-cyclo - [(N???? -1-lysine, 6-glycine) bradykinin] and cyclo - [(? -aminododecanoyl) bradykinin] and their use
DE2034118A1 (en) Xenogenic nucleic acids for enhancing antigenicity - of peptides and proteins
DE60118409T2 (en) METHOD OF MANUFACTURING IMMUNOGLOBULINS DIRECTED AGAINST HUMAN THYMOCYTES
DE2341798C2 (en) The octapeptide xenopsin and process for its production
EP0056594A1 (en) Thymosin-alpha-1 fragments and pharmaceutical compositions with immunoregulating action containing them
EP0133308B1 (en) Agent for controlling the appetite and process for its preparation
DE2815758C3 (en) Peptide complexes from organisms containing DNA
AT384812B (en) METHOD FOR PRODUCING NEW POLYPEPTIDES
EP0075925A2 (en) Process for producing an active ingredient specifically acting upon the nutritive centre as an appetizer, and the active ingredient obtained by the process
DE2708780A1 (en) NEW BLOOD SERUM PREPARATIONS, METHODS OF MANUFACTURING AND USE AS MEDICINAL PRODUCTS AND MEDICAL ADDITIVES

Legal Events

Date Code Title Description
8139 Disposal/non-payment of the annual fee